

32692

Customer Number

Patent
Case No.: 59091US005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor: WIGHTMAN, PAUL D.
Application No.: 10/595066 Confirmation No.: 2105
Filed: August 12, 2004
Title: LIPID-MODIFIED IMMUNE RESPONSE MODIFIERS

INFORMATION DISCLOSURE STATEMENT

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR §§ 1.56, 1.97, and 1.98, enclosed is a completed Form PTO-1449, citing references submitted for consideration by the Examiner. It is respectfully requested that the Examiner initial and return the enclosed Form PTO-1449 to indicate that each reference has been considered.

Copies of any cited foreign patents, foreign publications, non-patent literature documents, and any pending U.S. applications filed before June 30, 2003, are enclosed. Copies of any pending U.S. applications filed after June 30, 2003 that can be accessed on the USPTO's IFW system are not enclosed as per USPTO Waiver dated September 21, 2004. Copies of any U.S. patents and published U.S. patent applications are not enclosed.

If a first Office Action on the merits has been mailed prior to the mailing date of this document, please charge the fee for consideration of an Information Disclosure Statement set forth in 37 CFR § 1.17(p).

Respectfully submitted,

25 July 2006
Date

By: Dean A. Ersfeld
Dean A. Ersfeld, Reg. No.: 46,689
Telephone No.: 651-733-7830

Office of Intellectual Property Counsel
3M Innovative Properties Company
Facsimile No.: 651-736-383